Aerie Pharmaceuticals to Participate in Two Investor Conferences in December
01 December 2016 - 11:30PM
Business Wire
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class glaucoma therapies, today
announced that company management will participate in the following
conferences in December.
- Citi 2016 Global Healthcare Conference
- Attendee: Richard Rubino, Chief
Financial Officer
- Date: Thursday, December 8, 2016
- Location: New York, NY
- BMO Capital Markets 2016 Prescription
for Success Healthcare Conference
- Presenter: Vicente Anido, Jr., Ph.D.,
Chairman and Chief Executive Officer
- Presentation Date: Wednesday, December
14, 2016
- Presentation Time: 5:00pm E.T.
- Location: New York, NY
The BMO Capital Markets 2016 Prescription for Success Healthcare
Conference fireside chat discussion will be webcast live and may be
accessed by visiting Aerie's website at
http://investors.aeriepharma.com/. A replay of the webcast will be
available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with glaucoma and other
diseases of the eye. Aerie's two lead product candidates are
once-daily IOP-lowering therapies with novel mechanisms of action
to treat patients with glaucoma or ocular hypertension. The NDA
filing for Rhopressa™ (netarsudil ophthalmic solution) 0.02%
was originally submitted in the third quarter of 2016 and is
expected to be resubmitted in January 2017. The second product
candidate, Roclatan™ (netarsudil/latanoprost ophthalmic
solution) 0.02%/0.005%, which is a fixed dose combination of
Rhopressa™ and widely prescribed PGA latanoprost,
currently has two Phase 3 registration trials underway, named
Mercury 1 and Mercury 2. If these trials are successful, a
Roclatan™ NDA filing is expected to take place near year-end
2017. Aerie is also focused on the development of additional
product candidates and technologies in ophthalmology.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161201005128/en/
Aerie PharmaceuticalsRichard Rubino,
908-947-3540rrubino@aeriepharma.comorBurns McClellan, Inc., on
behalf of Aerie PharmaceuticalsAmi Bavishi,
212-213-0006abavishi@burnsmc.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2024 to May 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Aerie Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Aerie Pharmaceuticals, Inc. (MM) News Articles